1,080 results on '"Kastelein, John J.P."'
Search Results
202. Atherogenic Lipoprotein Particle Size and Concentrations and the Effect of Pravastatin in Children with Familial Hypercholesterolemia
203. Gene-load score of the renin–angiotensin–aldosterone system is associated with coronary heart disease in familial hypercholesterolaemia
204. Familial Defective Apolipoprotein B and Familial Hypobetalipoproteinemia in One Family: Two Neutralizing Mutations
205. Ultrasound imaging techniques for the evaluation of cardiovascular therapies
206. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study
207. High-density lipoprotein particle size and concentration and coronary risk
208. Cholesterol levels in small LDL particles predict the risk of coronary heart disease in the EPIC-Norfolk prospective population study
209. HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events
210. Role of the Apolipoprotein B–Apolipoprotein A-I Ratio in Cardiovascular Risk Assessment: A Case–Control Analysis in EPIC-Norfolk
211. Influence of LDL-receptor mutation type on age at first cardiovascular event in patients with familial hypercholesterolaemia
212. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study
213. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis
214. Diagnosing familial hypercholesterolaemia: the relevance of genetic testing
215. Metabolic Syndrome and Risk of Coronary, Cerebral, and Peripheral Vascular Disease in a Large Dutch Population With Familial Hypercholesterolemia
216. PLANT STANOLS DO NOT RESTORE ENDOTHELIAL FUNCTION IN PRE-PUBERTAL CHILDREN WITH FAMILIAL HYPERCHOLESTEROLEMIA DESPITE REDUCTION OF LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS
217. Endothelial Glycocalyx Damage Coincides With Microalbuminuria in Type 1 Diabetes
218. Loss of Endothelial Glycocalyx During Acute Hyperglycemia Coincides With Endothelial Dysfunction and Coagulation Activation In Vivo
219. Update of the Molecular Basis of Familial Hypercholesterolemia in The Netherlands
220. A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease
221. Functional interaction between −629C/A, −971G/A and −1337C/T polymorphisms in the CETP gene is a major determinant of promoter activity and plasma CETP concentration in the REGRESS Study
222. Age at repair and left ventricular mass in patients after repair of aortic coarctation
223. Metabolic Syndrome and Risk of Restenosis in Patients Undergoing Percutaneous Coronary Intervention
224. Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation
225. Local overexpression of C-type natriuretic peptide ameliorates vascular adaptation of porcine hemodialysis grafts
226. The cholesteryl ester transfer protein (CETP) TaqIB polymorphism in the cholesterol and recurrent events study: no interaction with the response to pravastatin therapy and no effects on cardiovascular outcome: A prospective analysis of the CETP TaqIB polymorphism on cardiovascular outcome and interaction with cholesterol-lowering therapy
227. Clinical, diagnostic and therapeutic aspects of (inherited) hypercholesterolemia
228. Atherosclerosis measured by B-Mode ultrasonography: effect of statin therapy on disease progression
229. Safety of rosuvastatin
230. Design and baseline characteristics of the Incremental Decrease in End Points through Aggressive Lipid Lowering study
231. Familial Defective Apolipoprotein B Versus Familial Hypercholesterolemia: An Assessment of Risk
232. Cost-Effectiveness Analysis of the Genetic Screening Program for Familial Hypercholesterolemia in the Netherlands
233. Clinical, Diagnostic, and Therapeutic Aspects of Familial Hypercholesterolemia
234. Advanced Method for the Identification of Patients with Inherited Hypercholesterolemia
235. Haplotype analysis of the CETP gene: not TaqIB, but the closely linked −629C→A polymorphism and a novel promoter variant are independently associated with CETP concentration
236. Measurement of subclinical atherosclerosis: beyond risk factor assessment
237. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin
238. Phenotypic variability in familial hypercholesterolaemia: an update
239. Long-term compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia
240. Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia: A Comparison with Gemfibrozil
241. Surrogate markers of atherosclerosis: impact of statins
242. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes
243. Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia: The Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) Study
244. Additional Efficacy of Milligram-Equivalent Doses of Atorvastatin over Simvastatin
245. Tailored Therapy to Fit Individual Profiles: Genetics and Coronary Artery Disease
246. Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease
247. 20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
248. Mendelian Randomization Study of ACLY and Cardiovascular Disease
249. Moving Targets
250. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.